Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Sofosbuvir/ACH-3102. Show all posts
Showing posts with label Sofosbuvir/ACH-3102. Show all posts
Saturday, April 25, 2015

Achillion Presents Results on ACH-3102 and ACH-3422 at EASL

›
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress - Two late breaker presentati...
Monday, February 9, 2015

Achillion, Gilead drug cocktail cures hepatitis C in six weeks

›
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102 - Achillion achieves 100% SVR12 in...
Tuesday, November 11, 2014

AASLD- Achillion Reports 100% SVR12 With ACH-3102 and Sovaldi

›
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) Achillion Achieves 100% SVR12 i...
Saturday, November 8, 2014

AASLD-Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 and Sofosbuvir

›
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) - Achillion Achieves 100% SVR...
Wednesday, October 8, 2014

AASLD - Achillion to Present HCV Data on ACH-3102/Sofosbuvir and Preclinical Profile of ACH-3422

›
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of ...
Friday, August 15, 2014

Achillion's hepatitis C drug shows promise in trial

›
Achillion's hepatitis C drug shows promise in trial (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experi...
Thursday, May 1, 2014

Hepatitis C-Achillion Begins Dosing In ACH-3422/ Initiated Phase 2 ACH-3102/Sofosbuvir trial

›
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A I...